Seminars in Hematology
Volume 46, Issue 2 , Pages 127-132 , April 2009

The Role of High-Dose Therapy With Autologous Stem Cell Support in the Era of Novel Agents

  • Michel Attal

      Affiliations

    • Centre Hospitalier de Purpan, Toulouse, France
    • Corresponding Author InformationAddress correspondence to Michel Attal, MD, Centre Hospitalier de Purpan, Place du Dr Baylac, 31059 Toulouse, France
    • ,
  • Jean-Luc Harousseau

      Affiliations

    • Centre Hospitalier Universitaire Hôtel-Dieu, Nantes, France

References 

  1. Harousseau JL, Shaughessy J, Richardson P. Multiple myeloma. Hematology ASCT Educ Program. 2004;235–256
  2. Barlogie B, Jagannath S, Vesole DH, et al. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood. 1997;89:789–793
  3. Palumbo A, Triolo S, Argentino C, et al. Dose-intensive melphalan with stem cell support is superior to standard treatment in elderly myeloma patients. Blood. 1999;94:1248–1253
  4. Lenhoff S, Hjorth M, Holmberg E, et al. Impact of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study. Blood. 2000;95:7–11
  5. Blade J, San Miguel JF, Fontanillas M, et al. Survival of multiple myeloma patients who are potential candidates for early high-dose therapy intensification/autotransplantation and who were conventionally treated. Blood. 1996;14:2167–2173
  6. Attal M, Harousseau JL, Stoppa AM, et al. A prospective randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med. 1996;335:91–97
  7. Child JA, Morgan GJ, Davies FE, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med. 2003;348:1875–1883
  8. Fermand JP, Ravaud P, Chevret S, et al. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: upfront or rescue treatment? (Results of a multicenter sequential randomized trial). Blood. 1998;92:3131–3136
  9. Palumbo A, Bringhen S, Petrucci MT, et al. Intermediate-dose melphalan improves survival of myeloma patients aged 50-70: results of a randomized controlled trial. Blood. 2004;104:3052–3057
  10. Blade J, Rosinol L, Sureda A, et al. High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish Cooperative Group PETHEMA. Blood. 2005;106:3755–3759
  11. Fermand JP, Katsahian S, Divine M, et al. High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Groupe Myelome-Autogreffe. J Clin Oncol. 2005;23:9227–9233
  12. Barlogie B, Kyle RA, Anderson KC, et al. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup trial S9321. J Clin Oncol. 2006;24:929–936
  13. Koreth J, Cutler CS, Djulbegovic B, et al. High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials. Biol Blood Marrow Transplant. 2007;13:183–196
  14. Attal M, Harousseau JL, Facon T, et al. Intergroupe Francophone du Myelome: single versus double autologous stem cell transplantation for multiple myeloma. N Engl J Med. 2003;349:2495–2502
  15. Harousseau JL, Attal M, Moreau P, et al. The prognostic impact of complete remission plus very good partial remission in a double-transplantation program for newly diagnosed multiple myeloma [abstract]. Blood. 2006;108:877a
  16. van de Velde HJK, Liu X, Chen G, Cakana A, Draedt W, Bayssas M. Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma. Haematologica. 2007;92:1399–1406
  17. Barlogie B, Jagannath S, Desikan KR, et al. Total therapy with tandem autotransplants for newly diagnosed multiple myeloma. Blood. 1999;93:55–65
  18. Sonneveld P, van der Holt B, Segeren CM, et al. Intermediate-dose melphalan compared with myeloablative treatment in multiple myeloma: long-term results of the Dutch Cooperative group HOVON 24 trial. Haematologica. 2007;92:928–935
  19. Cavo M, Tosi P, Zamagni E, et al. Prospective randomized study of single compared with double autologous stem cell transplantation for multiple myeloma: Bologna 96 clinical study. J Clin Oncol. 2007;25:2434–2441
  20. Rajkumar SV, Blood E, Vesole D, et al. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol. 2006;24:431–436
  21. Cavo M, Zamagni E, Tosi P, et al. Superiority of thalidomide and dexamethasone over vincristine-doxorubicine-dexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood. 2005;106:35–39
  22. Macro M, Divine M, Uzunban Y, et al. Dexamethasone + thalidomide compared to VAD as pre-transplant treatment in newly diagnosed multiple myeloma: a randomized trial [abstract]. Blood. 2006;108:22a
  23. Lokhorst HM, Schmidt-Wolf I, Sonneveld P, et al. Thalidomide in induction treatment increases the very good partial remission rate before and after high-dose therapy in previously untreated multiple myeloma. Haematologica. 2008;93:124–127
  24. Morgan GJ, Davies FE, Owen RG, et al. Thalidomide combinations improve response rates: results from the MRC IX study [abstract]. Blood. 2007;110:1051a
  25. Harousseau JL, Mathiot C, Attal M, et al. Velcade/dexamethasone versus VAD as induction treatment prior to autologous stem cell transplantation in newly diagnosed multiple myeloma: updated results of the IFM 2005/01 trial [abstract]. Blood. 2007;110:139a
  26. Cavo M, Patriarca F, Tacchetti P, et al. Bortezomib-thalidomide-dexamethasone vs thalidomide-dexamethasone in preparation for autologous stem-cell transplantation in newly diagnosed multiple myeloma [abstract]. Blood. 2007;110:30°
  27. Lacy MQ, Gertz MA, Dispenzieri A, et al. Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma. Mayo Clin Proc. 2007;82:1179–1184
  28. Rajkumar SV, Jacobus S, Callander N, et al. A randomized trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed multiple myeloma (E403): a trial coordinated by the Eastern Cooperative Oncology Group [abstract]. Blood. 2007;110:31a
  29. Richardson P, Jagannath S, Raje N, et al. Lenalidomide, bortezomib, and dexamethasone as front_line therapy for patients with multiple myeloma: preliminary results of a Phase 1/2 Study [abstract]. Blood. 2007;110:63a
  30. Hollmig K, Stover J, Talamo G, et al. Addition of bortezomib to high dose melphalan as an effective conditioning regimen with autologous stem cell support in multiple myeloma [abstract]. Blood. 2004;103:266a
  31. Attal M, Harousseau JL. Role of autologous stem-cell transplantation in multiple myeloma. Best Pract Res Clin Haematol. 2007;20:747–759
  32. Ladetto M, Pagliano G, Avonto I, et al. Consolidation with bortezomib, thalidomide and dexamethasone induces molecular remissions in autografted multiple myeloma patients [abstract]. Blood. 2007;110:163a
  33. Cunningham D, Powles R, Malpas JS, et al. A randomized trial of maintenance therapy with intron A following high dose Melphalan and ABMT in myeloma. Br J Haematol. 1998;102:195–202
  34. Barlogie B, Tricot G, Anaissie E, et al. Thalidomide and hematopoietic stem cell transplantation for multiple myeloma. N Engl J Med. 2006;354:1021–1030
  35. Barlogie B, Pineda-Roman M, Van Rhee F, et al. Thalidomide arm of total therapy II improves complete remission duration and survival in myeloma with metaphase cytogenetic abnormalities. Blood. 2008;112:3115–3121
  36. Attal M, Harousseau JL, Leyvraz S, et al. Maintenance therapy with thalidomide improves survival in multiple myeloma patients. Blood. 2006;15:3289–3294
  37. Abdelkefi A, Ladeb S, Torjman L, et al. Single autologous stem cell transplantation followed by maintenance therapy with thalidomide is superior to double autologous transplantation in multiple myeloma: results of a multicenter randomized clinical trial. Blood. 2008;111:1805–1810
  38. Spencer A, Prince HM, Roberts A, et al. Thalidomide improves survival when used following ASCT [abstract]. Haematologica. 2007;92:41–42
  39. Facon T, Mary JY, Hulin C, et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone.or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomized trial. Lancet. 2007;370:1209–1218
  40. Palumbo A, Bringhen S, Caravita T, et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomized controlled trial. Lancet. 2006;367:825–835
  41. San Miguel JF, Schlag R, Khuageva N, et al. MMY-3002: bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008;359:906–917
  42. Palumbo A, Falco P, Corradini P, et al. Melphalan, prednisone and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA-Italian Multiple Myeloma Network. J Clin Oncol. 2007;25:4459–4465

PII: S0037-1963(09)00034-1

doi: 10.1053/j.seminhematol.2009.02.006

Seminars in Hematology
Volume 46, Issue 2 , Pages 127-132 , April 2009

Article Tools